The pharmaceutical company Moderna announced that it began the last phase of clinical trials for the development of four new vaccines against latent infections, including chickenpox and herpes, as well as the norovirus responsible for gastroenteritis outbreaks.

The four vaccines against latent infections are for diseases caused by viruses of the herpesvirus family: cytomegalovirus (the infection that causes the most birth defects in the United States), Epstein-Barr virus (the main cause of acute infectious mononucleosis), herpes virus simplex and the varicella-zoster virus (responsible for chickenpox).

In addition, the pharmaceutical company is in the last phase of development of a vaccine against norovirus, which causes outbreaks of gastroenteritis around the world and about 200,000 deaths a year.

Moderna also took the opportunity to announce a new generation vaccine against Covid-19 effective for both the omicron BA.4 and BA.5 variants and the original strains of SARS-CoV-2.

The new generation of vaccine against Covid-19 has allowed the company to develop a vaccine candidate against flu and Covid-19 for people over 50 years of age.

The company valued the global endemic Covid-19 market at $10 billion annually.

With information from Doble Llave

(Reference image source: Mufid Majnun in Unsplash)

Visit our news channel on Google News and follow us to get accurate, interesting information and stay up to date with everything. You can also see our daily content on Twitter and Instagram

La entrada Moderna prepares to launch four vaccines apareció primero en Bitfinance.

The American laboratory Moderna closed 2021 with a net profit of 12,202 million dollars (10,982 million euros) compared to the losses of 747 million (672 million euros) that it recorded in the previous year, thanks to the millions of doses sold of Spikevax, your COVID-19 vaccine.

Between January and December, the firm invoiced 18,471 million (16,625 million euros), compared to the 803 million (723 million euros) that it entered in 2020. This change is due to the fact that the vaccines began to be marketed robustly in 2021.

Income from vaccines was 17,675 million (15,909 million euros), compared to 200 million (180 million euros) the previous year, while income from subsidies grew by 38.9 %, to 735 million dollars (€662 million).

The cost of goods sold was 2,617 million (2,356 million euros), practically without comparison with 2020 while selling expenses, general and administrative expenses multiplied by three, to 567 million (510 million euros). The research and development (R&D) item expanded by 45.3 %, to 1,991 million (1,792 million euros).

Only in the fourth quarter of the year, the laboratory registered net profits of 4,868 million (4,382 million euros), compared to losses of 272 million (245 million euros) the previous year. Turnover stood at 7,211 million (6,490 million euros), compared to 571 million (514 million euros) in the last quarter of 2020.

 Source: dpa

La entrada Moderna earns $12 billion from its Spikevax vaccine apareció primero en Bitfinance.